Mechanistically, PTPN13 suppresses HCC progression by directly and competitively binding insulin-like growth factor 2 mRNA-binding protein 1 (IGF2BP1) to diminish the intracellular concentration of functional IGF2BP1, thereby promoting c-Myc mRNA degradation (70). Here, IGF2BP1 is linked to hepatocellular carcinoma.